news
FDA-approved drug may block resistance to anti-angiogenesis therapy
General study identifies targetable pathway that induces immunosuppressive environment in colorectal cancer...
List view / Grid view
Immunotherapy
whitepaper
Application note: Quantitative Analysis of Immunosuppressant Drugs in Serum Using a QSight 110 Triple Quadrupole Mass Spectrometer
This application note describes a sensitive, fast and accurate LC/MS/MS quantitation method utilising a QSight™ 110 Triple Quadrupole Mass Spectrometer for the simultaneous analysis of the immunosuppressant drugs tacrolimus, sirolimus and cyclosporine A in serum, using everolimus as an internal standard...
news
Immunotherapy combination effective at killing cancer cells
Researchers have recently discovered an immunotherapy that uses existing cancer drugs in a whole new way...
news
Uncovering the cause of immunotherapy resistance in tumours
Scientists have uncovered a key factor in the development of immunotherapy resistance in the case of cutaneous melanoma. This could potentially lead to future improvements in cancer therapy.
news
Sandoz receives EU approval for Erelzi (biosimilar etanercept)
The European Commission (EC) has approved Sandoz’ (a Novartis division) Erelzi (biosimilar etanercept) for use in Europe, to treat inflammatory diseases...
news
Collaboration is ‘game changer’ in delivering cell and gene therapies
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
news
Roche receives FDA approval for bladder cancer biomarker assay
5 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma...
article
How Panacea is paving the way for vaccine immunotherapies
29 March 2017 | By Niamh Marriott, Junior Editor
We caught up with the CEO & CSO of Panacea for the latest on vaccine immunotherapies - "As a scientist, as long as you are observant and persistent, you may come up with breakthrough discoveries"
news
Immunotherapy treatment fast-tracked under UK’s access to medicines scheme
2 February 2017 | By Niamh Marriott, Digital Editor
From today, UK patients with an incurable form of bladder cancer can access the new immunotherapy, atezolizumab, following a positive Scientific Opinion...
news
Up to 10-fold increase in assay sensitivity – discover Morffi™ at MEDICA 2016
3 November 2016 | By BBI Solutions
BBI Solutions will be showcasing its Morffi™ signal enhancement technology on Stand F26 in Hall 1 at MEDICA 2016...
news
‘Game-changing’ immunotherapy doubles head and neck cancer survival
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer...
news
BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays
23 September 2016 | By BBI Solutions
BBI Solutions has launched Morffi™, a novel conjugate blocking technology that enhances signal intensity and improves the sensitivity of lateral flow immunoassays, at the Lateral Flow Test Development seminar in Seattle, USA, on the 20th September...
news
Cancer immunotherapy drugs linked to autoimmune diseases
24 June 2016 | By Victoria White, Digital Content Producer
Some cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at a higher-than-normal risk of developing autoimmune diseases...
news
Chemo may boost immunotherapy power in ovarian cancer
15 June 2016 | By Victoria White, Digital Content Producer
A study has found that women with ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy...
news
Study describes extraordinarily potent mRNA cancer immunotherapy
2 June 2016 | By Victoria White, Digital Content Producer
BioNTech has announced the publication of a study that describes the first example of a clinically relevant and systemic mRNA cancer immunotherapy...
